The enhanced intestinal permeability of infant mice enables oral protein and macromolecular absorption without delivery technology

[Display omitted] Oral delivery of macromolecular drugs is the most patient-preferred route of administration because it is painless and convenient. Over the past 30 years, significant attention has been paid to oral protein delivery in adults. Unfortunately, there is an outstanding need for similar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2021-01, Vol.593, p.120120-120120, Article 120120
Hauptverfasser: Gleeson, John P., Fein, Katherine C., Chaudhary, Namit, Doerfler, Rose, Newby, Alexandra N., Whitehead, Kathryn A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 120120
container_issue
container_start_page 120120
container_title International journal of pharmaceutics
container_volume 593
creator Gleeson, John P.
Fein, Katherine C.
Chaudhary, Namit
Doerfler, Rose
Newby, Alexandra N.
Whitehead, Kathryn A.
description [Display omitted] Oral delivery of macromolecular drugs is the most patient-preferred route of administration because it is painless and convenient. Over the past 30 years, significant attention has been paid to oral protein delivery in adults. Unfortunately, there is an outstanding need for similar efforts in infants, a patient population with distinct intestinal physiology and treatment needs. Here, we assess the intestinal permeability of neonatal and infant mice to determine the feasibility of orally delivering peptide and protein drugs without permeation enhancers or other assistance. Using the non-everted gut sac model, we found that macromolecular permeability depended on molecular size, mouse age, and intestinal tissue type using model dextrans. For example, the apparent permeability of 70 kDa FITC-Dextran (FD70) in infant small intestinal tissue was 2-5-fold higher than in adult tissue. As mice aged, the expression of barrier-forming and pore-forming tight junction proteins increased and decreased, respectively. The in vivo oral absorption of 4 kDa FITC-Dextran (FD4) and FD70 was significantly higher in younger mice, and there was a fourfold increase in oral absorption of the 80 kDa protein lactoferrin compared to adults. Oral gavage of insulin (5 IU/kg) reduced blood glucose levels in infants by >20% at 2 and 3 h but had no effect in adults. Oral insulin had 35% and
doi_str_mv 10.1016/j.ijpharm.2020.120120
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7790917</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517320311054</els_id><sourcerecordid>2465754079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-ef19ad48f7078cf0980c53bf71841f6ede37d9f2bc80caf12a824f566543f32b3</originalsourceid><addsrcrecordid>eNqFkc2L1DAYxoMo7uzon6Dk6KVjPtqmvSiyqCsseFnPIU3fbDOkyZiks8zVv9yUGRc9CYEX8vzeD54HoTeU7Cih7fv9zu4Pk4rzjhFW_hgp7xna0E7witeifY42hIuuaqjgV-g6pT0hpGWUv0RXnLO6Zw3ZoF_3E2Dwk_IaRmx9hpStVw4fIM6gButsPuFgimSUz3i2euXV4CDhEFcwhgzWY-VHPCsdwxwc6MWpiNWQQjxkGzx-tHkKS8YjOHuEeMIZ9OSDCw-nV-iFUS7B60vdoh9fPt_f3FZ3379-u_l0V-m6FbkCQ3s11p0RRHTakL4juuGDEbSrqWlhBC7G3rBBF0EZylTHatO0bVNzw9nAt-jDee5hGWYYNfhc7peHaGcVTzIoK_9VvJ3kQzhKIXrSFxe36N1lQAw_l2KUnG3S4JzyEJYkWd02oqmJ6AvanNHiR0oRzNMaSuSan9zLS35yzU-e8yt9b_--8anrT2AF-HgGoDh1tBBl0hbW8GwEneUY7H9W_AYKg7PJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2465754079</pqid></control><display><type>article</type><title>The enhanced intestinal permeability of infant mice enables oral protein and macromolecular absorption without delivery technology</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><creator>Gleeson, John P. ; Fein, Katherine C. ; Chaudhary, Namit ; Doerfler, Rose ; Newby, Alexandra N. ; Whitehead, Kathryn A.</creator><creatorcontrib>Gleeson, John P. ; Fein, Katherine C. ; Chaudhary, Namit ; Doerfler, Rose ; Newby, Alexandra N. ; Whitehead, Kathryn A.</creatorcontrib><description>[Display omitted] Oral delivery of macromolecular drugs is the most patient-preferred route of administration because it is painless and convenient. Over the past 30 years, significant attention has been paid to oral protein delivery in adults. Unfortunately, there is an outstanding need for similar efforts in infants, a patient population with distinct intestinal physiology and treatment needs. Here, we assess the intestinal permeability of neonatal and infant mice to determine the feasibility of orally delivering peptide and protein drugs without permeation enhancers or other assistance. Using the non-everted gut sac model, we found that macromolecular permeability depended on molecular size, mouse age, and intestinal tissue type using model dextrans. For example, the apparent permeability of 70 kDa FITC-Dextran (FD70) in infant small intestinal tissue was 2-5-fold higher than in adult tissue. As mice aged, the expression of barrier-forming and pore-forming tight junction proteins increased and decreased, respectively. The in vivo oral absorption of 4 kDa FITC-Dextran (FD4) and FD70 was significantly higher in younger mice, and there was a fourfold increase in oral absorption of the 80 kDa protein lactoferrin compared to adults. Oral gavage of insulin (5 IU/kg) reduced blood glucose levels in infants by &gt;20% at 2 and 3 h but had no effect in adults. Oral insulin had 35% and &lt;1% of the pharmacodynamic effect of a 1 IU/kg subcutaneous dose in infants and adults, as measured by area above the curve. These data indicate that the uniquely leaky nature of the infantile intestine may support the oral delivery of biologics without the need for traditional oral delivery technology.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2020.120120</identifier><identifier>PMID: 33249250</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Intestinal permeability ; Oral drug delivery ; Pediatric therapy ; Protein delivery ; Tight junctions</subject><ispartof>International journal of pharmaceutics, 2021-01, Vol.593, p.120120-120120, Article 120120</ispartof><rights>2020 The Authors</rights><rights>Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-ef19ad48f7078cf0980c53bf71841f6ede37d9f2bc80caf12a824f566543f32b3</citedby><cites>FETCH-LOGICAL-c467t-ef19ad48f7078cf0980c53bf71841f6ede37d9f2bc80caf12a824f566543f32b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2020.120120$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,778,782,883,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33249250$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gleeson, John P.</creatorcontrib><creatorcontrib>Fein, Katherine C.</creatorcontrib><creatorcontrib>Chaudhary, Namit</creatorcontrib><creatorcontrib>Doerfler, Rose</creatorcontrib><creatorcontrib>Newby, Alexandra N.</creatorcontrib><creatorcontrib>Whitehead, Kathryn A.</creatorcontrib><title>The enhanced intestinal permeability of infant mice enables oral protein and macromolecular absorption without delivery technology</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted] Oral delivery of macromolecular drugs is the most patient-preferred route of administration because it is painless and convenient. Over the past 30 years, significant attention has been paid to oral protein delivery in adults. Unfortunately, there is an outstanding need for similar efforts in infants, a patient population with distinct intestinal physiology and treatment needs. Here, we assess the intestinal permeability of neonatal and infant mice to determine the feasibility of orally delivering peptide and protein drugs without permeation enhancers or other assistance. Using the non-everted gut sac model, we found that macromolecular permeability depended on molecular size, mouse age, and intestinal tissue type using model dextrans. For example, the apparent permeability of 70 kDa FITC-Dextran (FD70) in infant small intestinal tissue was 2-5-fold higher than in adult tissue. As mice aged, the expression of barrier-forming and pore-forming tight junction proteins increased and decreased, respectively. The in vivo oral absorption of 4 kDa FITC-Dextran (FD4) and FD70 was significantly higher in younger mice, and there was a fourfold increase in oral absorption of the 80 kDa protein lactoferrin compared to adults. Oral gavage of insulin (5 IU/kg) reduced blood glucose levels in infants by &gt;20% at 2 and 3 h but had no effect in adults. Oral insulin had 35% and &lt;1% of the pharmacodynamic effect of a 1 IU/kg subcutaneous dose in infants and adults, as measured by area above the curve. These data indicate that the uniquely leaky nature of the infantile intestine may support the oral delivery of biologics without the need for traditional oral delivery technology.</description><subject>Intestinal permeability</subject><subject>Oral drug delivery</subject><subject>Pediatric therapy</subject><subject>Protein delivery</subject><subject>Tight junctions</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkc2L1DAYxoMo7uzon6Dk6KVjPtqmvSiyqCsseFnPIU3fbDOkyZiks8zVv9yUGRc9CYEX8vzeD54HoTeU7Cih7fv9zu4Pk4rzjhFW_hgp7xna0E7witeifY42hIuuaqjgV-g6pT0hpGWUv0RXnLO6Zw3ZoF_3E2Dwk_IaRmx9hpStVw4fIM6gButsPuFgimSUz3i2euXV4CDhEFcwhgzWY-VHPCsdwxwc6MWpiNWQQjxkGzx-tHkKS8YjOHuEeMIZ9OSDCw-nV-iFUS7B60vdoh9fPt_f3FZ3379-u_l0V-m6FbkCQ3s11p0RRHTakL4juuGDEbSrqWlhBC7G3rBBF0EZylTHatO0bVNzw9nAt-jDee5hGWYYNfhc7peHaGcVTzIoK_9VvJ3kQzhKIXrSFxe36N1lQAw_l2KUnG3S4JzyEJYkWd02oqmJ6AvanNHiR0oRzNMaSuSan9zLS35yzU-e8yt9b_--8anrT2AF-HgGoDh1tBBl0hbW8GwEneUY7H9W_AYKg7PJ</recordid><startdate>20210125</startdate><enddate>20210125</enddate><creator>Gleeson, John P.</creator><creator>Fein, Katherine C.</creator><creator>Chaudhary, Namit</creator><creator>Doerfler, Rose</creator><creator>Newby, Alexandra N.</creator><creator>Whitehead, Kathryn A.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210125</creationdate><title>The enhanced intestinal permeability of infant mice enables oral protein and macromolecular absorption without delivery technology</title><author>Gleeson, John P. ; Fein, Katherine C. ; Chaudhary, Namit ; Doerfler, Rose ; Newby, Alexandra N. ; Whitehead, Kathryn A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-ef19ad48f7078cf0980c53bf71841f6ede37d9f2bc80caf12a824f566543f32b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Intestinal permeability</topic><topic>Oral drug delivery</topic><topic>Pediatric therapy</topic><topic>Protein delivery</topic><topic>Tight junctions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gleeson, John P.</creatorcontrib><creatorcontrib>Fein, Katherine C.</creatorcontrib><creatorcontrib>Chaudhary, Namit</creatorcontrib><creatorcontrib>Doerfler, Rose</creatorcontrib><creatorcontrib>Newby, Alexandra N.</creatorcontrib><creatorcontrib>Whitehead, Kathryn A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gleeson, John P.</au><au>Fein, Katherine C.</au><au>Chaudhary, Namit</au><au>Doerfler, Rose</au><au>Newby, Alexandra N.</au><au>Whitehead, Kathryn A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The enhanced intestinal permeability of infant mice enables oral protein and macromolecular absorption without delivery technology</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2021-01-25</date><risdate>2021</risdate><volume>593</volume><spage>120120</spage><epage>120120</epage><pages>120120-120120</pages><artnum>120120</artnum><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted] Oral delivery of macromolecular drugs is the most patient-preferred route of administration because it is painless and convenient. Over the past 30 years, significant attention has been paid to oral protein delivery in adults. Unfortunately, there is an outstanding need for similar efforts in infants, a patient population with distinct intestinal physiology and treatment needs. Here, we assess the intestinal permeability of neonatal and infant mice to determine the feasibility of orally delivering peptide and protein drugs without permeation enhancers or other assistance. Using the non-everted gut sac model, we found that macromolecular permeability depended on molecular size, mouse age, and intestinal tissue type using model dextrans. For example, the apparent permeability of 70 kDa FITC-Dextran (FD70) in infant small intestinal tissue was 2-5-fold higher than in adult tissue. As mice aged, the expression of barrier-forming and pore-forming tight junction proteins increased and decreased, respectively. The in vivo oral absorption of 4 kDa FITC-Dextran (FD4) and FD70 was significantly higher in younger mice, and there was a fourfold increase in oral absorption of the 80 kDa protein lactoferrin compared to adults. Oral gavage of insulin (5 IU/kg) reduced blood glucose levels in infants by &gt;20% at 2 and 3 h but had no effect in adults. Oral insulin had 35% and &lt;1% of the pharmacodynamic effect of a 1 IU/kg subcutaneous dose in infants and adults, as measured by area above the curve. These data indicate that the uniquely leaky nature of the infantile intestine may support the oral delivery of biologics without the need for traditional oral delivery technology.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33249250</pmid><doi>10.1016/j.ijpharm.2020.120120</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2021-01, Vol.593, p.120120-120120, Article 120120
issn 0378-5173
1873-3476
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7790917
source Elsevier ScienceDirect Journals Complete - AutoHoldings
subjects Intestinal permeability
Oral drug delivery
Pediatric therapy
Protein delivery
Tight junctions
title The enhanced intestinal permeability of infant mice enables oral protein and macromolecular absorption without delivery technology
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T14%3A28%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20enhanced%20intestinal%20permeability%20of%20infant%20mice%20enables%20oral%20protein%20and%20macromolecular%20absorption%20without%20delivery%20technology&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Gleeson,%20John%20P.&rft.date=2021-01-25&rft.volume=593&rft.spage=120120&rft.epage=120120&rft.pages=120120-120120&rft.artnum=120120&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2020.120120&rft_dat=%3Cproquest_pubme%3E2465754079%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2465754079&rft_id=info:pmid/33249250&rft_els_id=S0378517320311054&rfr_iscdi=true